Cargando…
Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130332/ https://www.ncbi.nlm.nih.gov/pubmed/27994642 http://dx.doi.org/10.3332/ecancer.2016.686 |
_version_ | 1782470715088306176 |
---|---|
author | van Harten, WH Retèl, VP |
author_facet | van Harten, WH Retèl, VP |
author_sort | van Harten, WH |
collection | PubMed |
description | The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement. |
format | Online Article Text |
id | pubmed-5130332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-51303322016-12-19 Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology van Harten, WH Retèl, VP Ecancermedicalscience Policy The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement. Cancer Intelligence 2016-10-28 /pmc/articles/PMC5130332/ /pubmed/27994642 http://dx.doi.org/10.3332/ecancer.2016.686 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Policy van Harten, WH Retèl, VP Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology |
title | Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology |
title_full | Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology |
title_fullStr | Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology |
title_full_unstemmed | Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology |
title_short | Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology |
title_sort | close cooperation with health technology assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology |
topic | Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130332/ https://www.ncbi.nlm.nih.gov/pubmed/27994642 http://dx.doi.org/10.3332/ecancer.2016.686 |
work_keys_str_mv | AT vanhartenwh closecooperationwithhealthtechnologyassessmentexpertiseiscrucialforimplementationandultimatelyreimbursementofinnovationsinoncology AT retelvp closecooperationwithhealthtechnologyassessmentexpertiseiscrucialforimplementationandultimatelyreimbursementofinnovationsinoncology |